1
|
Papageorgiou EP, Zhang H, Giverts S, Park C, Boser BE, Anwar M. Real-time cancer detection with an integrated lensless fluorescence contact imager. BIOMEDICAL OPTICS EXPRESS 2018; 9:3607-3623. [PMID: 30338143 PMCID: PMC6191610 DOI: 10.1364/boe.9.003607] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 06/14/2018] [Accepted: 06/29/2018] [Indexed: 06/08/2023]
Abstract
Microscopic tumor cell foci left in a patient after surgery significantly increase the chance of cancer recurrence. However, fluorescence microscopes used for intraoperative navigation lack the necessary sensitivity for imaging microscopic disease and are too bulky to maneuver within the resection cavity. We have developed a scalable chip-scale fluorescence contact imager for detecting microscopic cancer in vivo and in real-time. The imager has been characterized under simulated in vivo conditions using ex vivo samples, providing strong evidence that our device can be used in vivo. Angle-selective gratings enhance the resolution of the imager without impacting its physical size. We demonstrate detection of cancer cell clusters containing as few as 25 HCC1569 breast cancer cells and 400 LNCaP prostate cancer cells with integration times of only 50 ms and 70 ms, respectively. A cell cluster recognition algorithm is used to achieve both a sensitivity and specificity of 92 % for HCC1569 cell samples, indicating the reliability of the imager. The signal-to-noise ratio (SNR) degradation with increased separation is only 1.5 dB at 250 μm. Blood scattering and absorption reduce the SNR by less than 2 dB for typical concentrations. Moreover, HER2+ breast cancer tissue taken from a patient is distinguished from normal breast tissue with an integration time of only 75 ms.
Collapse
Affiliation(s)
- Efthymios P. Papageorgiou
- Electrical Engineering and Computer Sciences Department, University of California, Berkeley, California 94720,
USA
| | - Hui Zhang
- Department of Radiation Oncology, University of California, San Francisco, California 94158,
USA
| | - Simeon Giverts
- Electrical Engineering and Computer Sciences Department, University of California, Berkeley, California 94720,
USA
| | - Catherine Park
- Department of Radiation Oncology, University of California, San Francisco, California 94158,
USA
| | - Bernhard E. Boser
- Electrical Engineering and Computer Sciences Department, University of California, Berkeley, California 94720,
USA
| | - Mekhail Anwar
- Department of Radiation Oncology, University of California, San Francisco, California 94158,
USA
| |
Collapse
|
2
|
Napp J, Stammes MA, Claussen J, Prevoo HA, Sier CF, Hoeben FJ, Robillard MS, Vahrmeijer AL, Devling T, Chan AB, de Geus-Oei LF, Alves F. Fluorescence- and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma. Int J Cancer 2018; 142:2118-2129. [DOI: 10.1002/ijc.31236] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Revised: 12/04/2017] [Accepted: 12/14/2017] [Indexed: 01/30/2023]
Affiliation(s)
- Joanna Napp
- Institute of Interventional and Diagnostic Radiology, University Medical Center Göttingen; Göttingen Lower Saxony Germany
- Clinic of Haematology and Medical Oncology; University Medical Center Göttingen; Göttingen Lower Saxony Germany
- Translational Molecular Imaging, Max-Planck-Institute of Experimental Medicine; Göttingen Lower Saxony Germany
| | - Marieke A. Stammes
- Percuros B.V., AE Enschede; The Netherlands
- Department of Radiology; Leiden University Medical Center; RC Leiden The Netherlands
| | - Jing Claussen
- iThera Medical GmbH, Zielstattstrasse; Munich Germany
| | | | | | | | - Marc S. Robillard
- Tagworks Pharmaceuticals, Geert Grooteplein Zuid 10; GA Nijmegen The Netherlands
| | | | - Tim Devling
- iThera Medical GmbH, Zielstattstrasse; Munich Germany
| | | | - Lioe-Fee de Geus-Oei
- Department of Radiology; Leiden University Medical Center; RC Leiden The Netherlands
- Biomedical Photonic Imaging Group, MIRA Institute, University of Twente; AE Enschede The Netherlands
| | - Frauke Alves
- Institute of Interventional and Diagnostic Radiology, University Medical Center Göttingen; Göttingen Lower Saxony Germany
- Clinic of Haematology and Medical Oncology; University Medical Center Göttingen; Göttingen Lower Saxony Germany
- Translational Molecular Imaging, Max-Planck-Institute of Experimental Medicine; Göttingen Lower Saxony Germany
| |
Collapse
|
3
|
Handgraaf HJM, Boonstra MC, Prevoo HAJM, Kuil J, Bordo MW, Boogerd LSF, Sibinga Mulder BG, Sier CFM, Vinkenburg-van Slooten ML, Valentijn ARPM, Burggraaf J, van de Velde CJH, Frangioni JV, Vahrmeijer AL. Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types. Oncotarget 2017; 8:21054-21066. [PMID: 28416744 PMCID: PMC5400565 DOI: 10.18632/oncotarget.15486] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Accepted: 02/07/2017] [Indexed: 12/11/2022] Open
Abstract
Incomplete resections and damage to critical structures increase morbidity and mortality of patients with cancer. Targeted intraoperative fluorescence imaging aids surgeons by providing real-time visualization of tumors and vital structures. This study evaluated the tumor-targeted zwitterionic near-infrared fluorescent peptide cRGD-ZW800-1 as tracer for intraoperative imaging of multiple cancer types. cRGD-ZW800-1 was validated in vitro on glioblastoma (U-87 MG) and colorectal (HT-29) cell lines. Subsequently, the tracer was tested in orthotopic mouse models with HT-29, breast (MCF-7), pancreatic (BxPC-3), and oral (OSC-19) tumors. Dose-ranging studies, including doses of 0.25, 1.0, 10, and 30 nmol, in xenograft tumor models suggest an optimal dose of 10 nmol, corresponding to a human equivalent dose of 63 μg/kg, and an optimal imaging window between 2 and 24 h post-injection. The mean half-life of cRGD-ZW800-1 in blood was 25 min. Biodistribution at 4 h showed the highest fluorescence signals in tumors and kidneys. In vitro and in vivo competition experiments showed significantly lower fluorescence signals when U-87 MG cells (minus 36%, p = 0.02) or HT-29 tumor bearing mice (TBR at 4 h 3.2 ± 0.5 vs 1.8 ± 0.4, p = 0.03) were simultaneously treated with unlabeled cRGD. cRGD-ZW800-1 visualized in vivo all colorectal, breast, pancreatic, and oral tumor xenografts in mice. Screening for off-target interactions, cRGD-ZW800-1 showed only inhibition of COX-2, likely due to binding of cRGD-ZW800-1 to integrin αVβ3. Due to its recognition of various integrins, which are expressed on malignant and neoangiogenic cells, it is expected that cRGD-ZW800-1 will provide a sensitive and generic tool to visualize cancer during surgery.
Collapse
Affiliation(s)
| | - Martin C Boonstra
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | | | - Joeri Kuil
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
| | | | - Leonora S F Boogerd
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | | | - Cornelis F M Sier
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | | | - A Rob P M Valentijn
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
| | - Jacobus Burggraaf
- Centre for Human Drug Research, Leiden, The Netherlands.,Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands
| | | | - John V Frangioni
- Curadel, LLC, Marlborough, MA, U.S.A.,Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, U.S.A.,Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, U.S.A
| | | |
Collapse
|